These findings provide a new mechanism to explain how dyslipidemia involving increased levels of cholesterol-rich lipoproteins and decreased levels of cholesterol efflux promoting HDL (44) can lead to NLRP3 inflammasome activation and increased atherosclerosis. Here, NLRP3 is linked to metabolic syndrome.